These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 12812198)

  • 21. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
    Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Exceptional pancytopenia secondary to treatment with pegylated interferon and ribavirin].
    Wikman Jorgensen PE; Jover Díaz FM; Cuadrado Pastor JM
    Gastroenterol Hepatol; 2007 Apr; 30(4):253. PubMed ID: 17408558
    [No Abstract]   [Full Text] [Related]  

  • 23. [Antiviral treatments during cirrhosis].
    Bronowicki JP
    Gastroenterol Clin Biol; 2006; 30(6-7):899-902. PubMed ID: 16885876
    [No Abstract]   [Full Text] [Related]  

  • 24. Managing adverse effects of interferon-alfa and ribavirin in combination therapy for HCV.
    Slim J; Afridi MS
    Infect Dis Clin North Am; 2012 Dec; 26(4):917-29. PubMed ID: 23083824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Healing of chronic hepatitis C following 12 weeks of therapy with peginterferon-alpha and ribavirin].
    Barreales M; Castellano G; Fernández I; Muñoz R; Manzano M; Solís Herruzo JA
    Rev Esp Enferm Dig; 2007 Dec; 99(12):738-40. PubMed ID: 18290706
    [No Abstract]   [Full Text] [Related]  

  • 26. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
    Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
    Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Summaries for patients. Duration and dose of antiviral treatment for chronic hepatitis C.
    Ann Intern Med; 2004 Mar; 140(5):I67. PubMed ID: 14996694
    [No Abstract]   [Full Text] [Related]  

  • 28. Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders.
    Rustgi VK; Lee WM; Lawitz E; Gordon SC; Afdhal N; Poordad F; Bonkovsky HL; Bengtsson L; Chandorkar G; Harding M; McNair L; Aalyson M; Alam J; Kauffman R; Gharakhanian S; McHutchison JG;
    Hepatology; 2009 Dec; 50(6):1719-26. PubMed ID: 19852040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial.
    Shoeb D; Dearden J; Weatherall A; Bargery C; Moreea S; Alam S; White E; Vila X; Freshwater D; Ryder S; Mills PR; Alexander GJ; Forton D; Foster GR
    J Hepatol; 2014 Apr; 60(4):699-705. PubMed ID: 24291239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Anti-viral therapy of type C chronic hepatitis. 3. New development in anti-viral therapy of type C chronic hepatitis--Peg-IFN/ribavirin combination therapy and a new anti-viral treatment].
    Hiramatsu N
    Nihon Naika Gakkai Zasshi; 2008 Jan; 97(1):75-81. PubMed ID: 18360974
    [No Abstract]   [Full Text] [Related]  

  • 31. Autoimmune thrombocytopenia induced by PEG-IFN-alpha2b plus ribavirin in hepatitis C.
    Sagir A; Wettstein M; Heintges T; Häussinger D
    Dig Dis Sci; 2002 Mar; 47(3):562-3. PubMed ID: 11911342
    [No Abstract]   [Full Text] [Related]  

  • 32. Unilateral hearing loss due to pegylated interferon-α2b and ribavirin therapy.
    Jain S; Midha V; Sood A
    Indian J Gastroenterol; 2011 Sep; 30(5):239-40. PubMed ID: 21986854
    [No Abstract]   [Full Text] [Related]  

  • 33. [Treatment of cirrhotics].
    Galdame O; Jorge A; Sordá J
    Acta Gastroenterol Latinoam; 2005 Jun; 35 Suppl 1():S42-5. PubMed ID: 20214300
    [No Abstract]   [Full Text] [Related]  

  • 34. A chronic subdural hematoma in a patient receiving combination therapy with pegylated interferon alfa-2b and ribavirin for chronic hepatitis C.
    Goto T; Ohshima S; Miura K; Shibuya T; Sato W; Dohmen T; Kamada K; Kanata R; Sakai T; Chiba M; Sugimoto Y; Minami S; Ohnishi H
    Intern Med; 2013; 52(18):2057-60. PubMed ID: 24042512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
    Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Antiviral treatment in liver cirrhosis due to hepatitis C virus].
    Martínez-Bauer E; Forns X
    Gastroenterol Hepatol; 2003 May; 26(5):303-6. PubMed ID: 12732104
    [No Abstract]   [Full Text] [Related]  

  • 37. The "pegylated" story continues--perhaps because both ends (α2a and α2b) are true?
    Reiberger T; Peck-Radosavljevic M
    J Hepatol; 2012 Jul; 57(1):226-8; author reply 229. PubMed ID: 22390901
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment for chronic hepatitis C.
    Bacon BR
    Curr Gastroenterol Rep; 2003 Feb; 5(1):1-2. PubMed ID: 12530942
    [No Abstract]   [Full Text] [Related]  

  • 39. Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases.
    Buti M; Valdés A; Sánchez-Avila F; Esteban R; Lurie Y
    Hepatology; 2003 May; 37(5):1226-7. PubMed ID: 12717407
    [No Abstract]   [Full Text] [Related]  

  • 40. Sofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and review.
    Mucenic M; Brandão ABM; Marroni CA; Fleck Junior AM; Zanotelli ML; Leipnitz I; Meine MH; Kiss G; Martini J; Schlindwein ES; Costabeber AM; Sacco FKR; Rossato G; Cantisani GPC
    Rev Inst Med Trop Sao Paulo; 2019 Feb; 61():e12. PubMed ID: 30785566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.